Business Context and Reporting Period
This Form 8-K filing by E. I. du Pont de Nemours and Company (DuPont) reports on events occurring at the Annual Meeting of Stockholders held on April 27, 2011. The filing details the election of directors, the ratification of auditors, and the voting results on various management and stockholder proposals.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
A total of 759,706,972 shares were voted, representing 82.01% of shares entitled to vote. Key outcomes include:
- Equity Plan Approval: Stockholders approved the amended Equity and Incentive Plan, increasing available shares by 50 million and extending the maximum term for stock options from seven to ten years.
- Director Elections: All 10 nominees were elected to the Board of Directors.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm.
- Executive Compensation: The advisory vote on executive compensation was approved. Stockholders also voted to hold annual executive compensation votes.
- Stockholder Proposals Rejected: Three stockholder proposals were not approved:
- Amending bylaws to allow 10% shareholders to call special meetings.
- Reviewing internal controls regarding genetically modified organisms.
- Preparing a report on senior executive compensation packages.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, or specific business risks. It notes that the approval of the Amended Plan re-approved performance goals for Section 162(m) tax compliance. The document references the 2011 Proxy Statement for full details on the Amended Plan and voting proposals.
Investor Verification Checklist
- Verify the specific terms of the "Amended Plan" in the 2011 Proxy Statement (Appendix B) regarding the 50 million share increase and vesting acceleration rules.
- Confirm the composition of the newly elected Board of Directors and their tenure.
- Review the rationale for the rejection of the stockholder proposal regarding genetically modified organisms, given DuPont's business exposure.
- Monitor future filings for the implementation of the annual executive compensation voting schedule.